Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 20 10:05AM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.12 Insider Own58.66% Shs Outstand35.88M Perf Week-17.20%
Market Cap145.01M Forward P/E- EPS next Y-1.92 Insider Trans0.00% Shs Float15.54M Perf Month10.56%
Income-82.78M PEG- EPS next Q-0.55 Inst Own39.10% Short Float5.66% Perf Quarter20.21%
Sales0.00M P/S- EPS this Y9.96% Inst Trans28.17% Short Ratio5.33 Perf Half Y7.48%
Book/sh2.76 P/B1.40 EPS next Y-0.38% ROA-52.16% Short Interest0.88M Perf Year-63.39%
Cash/sh2.70 P/C1.43 EPS next 5Y- ROE-60.18% 52W Range2.47 - 11.11 Perf YTD14.16%
Dividend Est.- P/FCF- EPS past 5Y- ROI-71.07% 52W High-65.27% Beta2.00
Dividend TTM- Quick Ratio12.38 Sales past 5Y0.00% Gross Margin- 52W Low56.22% ATR (14)0.50
Dividend Ex-Date- Current Ratio12.38 EPS Y/Y TTM0.09% Oper. Margin0.00% RSI (14)51.53 Volatility11.45% 15.42%
Employees69 Debt/Eq0.13 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price16.75
Option/ShortNo / Yes LT Debt/Eq0.12 EPS Q/Q2.59% Payout- Rel Volume0.59 Prev Close3.87
Sales Surprise- EPS Surprise17.45% Sales Q/Q- EarningsMay 07 AMC Avg Volume165.15K Price3.86
SMA202.60% SMA5015.01% SMA200-5.64% Trades Volume13,102 Change-0.29%
Date Action Analyst Rating Change Price Target Change
Dec-19-23Downgrade Morgan Stanley Equal-Weight → Underweight $13 → $4
Oct-18-23Initiated JMP Securities Mkt Outperform $23
Mar-31-23Initiated Mizuho Buy $15
Sep-16-22Initiated Wedbush Outperform $19
Aug-29-22Initiated H.C. Wainwright Buy $24
Feb-01-22Initiated Stifel Buy $24
Feb-01-22Initiated Morgan Stanley Equal-Weight $17
Feb-01-22Initiated Jefferies Buy $20
Feb-01-22Initiated Guggenheim Buy $23
Jun-11-24 06:30AM
Jun-05-24 12:55PM
May-30-24 07:05AM
May-28-24 12:00PM
07:40AM Loading…
May-08-24 07:40AM
May-07-24 10:55PM
Apr-17-24 04:05PM
Mar-26-24 01:53PM
Mar-20-24 07:05AM
Mar-13-24 07:05AM
Mar-12-24 07:05AM
04:25PM Loading…
Mar-06-24 04:25PM
Feb-29-24 04:05PM
Feb-07-24 04:05PM
Jan-03-24 04:30PM
Nov-22-23 04:05PM
Nov-16-23 04:05PM
Nov-07-23 07:05AM
Oct-18-23 09:52AM
Oct-17-23 07:05AM
Oct-05-23 04:01PM
Sep-26-23 07:05AM
Sep-11-23 12:00PM
Sep-08-23 04:05PM
Aug-08-23 07:05AM
04:05PM Loading…
Aug-07-23 04:05PM
Jun-01-23 07:00AM
May-10-23 07:00AM
May-09-23 07:00AM
May-08-23 08:30AM
Mar-30-23 07:00AM
Mar-22-23 07:00AM
Mar-21-23 07:00AM
Mar-02-23 04:00PM
Jan-03-23 07:00AM
Dec-15-22 04:01PM
Dec-14-22 04:01PM
Nov-29-22 05:23AM
Nov-28-22 07:00AM
Nov-10-22 07:00AM
Nov-07-22 07:00AM
Nov-02-22 12:43PM
Nov-01-22 07:00AM
Oct-12-22 07:58AM
Sep-14-22 09:55AM
Sep-01-22 07:00AM
Aug-29-22 09:55AM
Aug-12-22 09:55AM
Aug-08-22 07:00AM
Aug-02-22 07:00AM
Aug-01-22 07:00AM
Jul-28-22 07:00AM
Jun-09-22 09:58AM
Jun-07-22 07:00AM
Jun-01-22 07:00AM
May-12-22 07:00AM
Apr-20-22 07:00AM
Apr-08-22 12:33PM
Mar-25-22 06:30AM
Mar-21-22 07:00AM
Mar-03-22 04:05PM
Jan-27-22 01:46PM
Jan-11-22 04:01PM
Jan-06-22 11:07PM
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Magovcevic-Liebisch IvanaPresident and CEONov 20 '23Buy3.754,00015,000207,687Nov 20 06:34 PM